Adrafinil

Identification

Name
Adrafinil
Accession Number
DB08925
Type
Small Molecule
Groups
Withdrawn
Description

Adrafinil is a mild central nervous system stimulant drug used to relieve excessive sleepiness and inattention in elderly patients. It is also used off-label by individuals wishing to avoid fatigue, such as night workers or others who need to stay awake and alert for long periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States. It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission. [Wikipedia]

Synonyms
Not Available
External IDs
CRL-40028
International/Other Brands
Olmifon (Cephalon)
Categories
UNII
BI81Z4542G
CAS number
63547-13-7
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Used to relieve excessive sleepiness and inattention in elderly patients.

Pharmacodynamics

Adrafinil is a prodrug; it is primarily metabolized in vivo to modafinil, resulting in nearly identical pharmacological effects. Unlike modafinil, however, it takes time for the metabolite to accumulate to active levels in the bloodstream. Effects usually are apparent within 45–60 minutes when taken orally on an empty stomach.

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcebutololThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Acebutolol.
AcepromazineAcepromazine may decrease the vasoconstricting activities of Adrafinil.
AlfuzosinThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Alfuzosin.
AmitriptylineThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Amitriptyline.
AmoxapineAmoxapine may decrease the vasoconstricting activities of Adrafinil.
AripiprazoleAripiprazole may decrease the vasoconstricting activities of Adrafinil.
AsenapineAsenapine may decrease the vasoconstricting activities of Adrafinil.
AtenololThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Atenolol.
Benzylpenicilloyl PolylysineAdrafinil may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetaxololThe therapeutic efficacy of Adrafinil can be decreased when used in combination with Betaxolol.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D07348
PubChem Substance
347910387
Wikipedia
Adrafinil
ATC Codes
N06BX17 — Adrafinil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 08, 2013 14:30 / Updated on August 02, 2018 06:11